Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2008

View Archived Issues

Genentech presents preclinical, clinical data on GDC-0941

Exelixis discloses results on its investigational compounds for cancer

EA-230 lessens kidney damage in porcine peritonitis

SCIO-469 does not meet primary endpoint in a phase II rheumatoid arthritis study

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Anesiva discontinues Zingo, reports results from phase III trial of Adlea

Cell Therapeutics reports results from phase III trial of pixantrone in NHL

Almirall signs agreement with Pfizer to commercialize Astucor in Spain for cardiovascular protection

Sangamo reports results from diabetic neuropathy trial SB-509-601

Lorus completes IND-enabling studies for LOR-253

INNO-406 shows encouraging responses in phase I chronic myeloid leukemia trial

Phase II IMC-1121B study commences in first-line treatment of NSCLC

TNFerade receives FDA fast track designation for pancreatic cancer

Two phase I studies with novel cancer vaccine in two different routes of administration

Marillion and Bracco sign license agreement for cancer drug 177Lu-AMBA

Lipocine completes clinical study establishing feasibility of once-daily ziprasidone

Alba Therapeutics enrolls first European patient in global phase IIb larazotide study

Raptor reports results from phase IIa study of Convivia in ALDH2 deficiency

Novartis reports results from AGELESS study of direct renin inhibitor Rasilez

Acrux adds novel formulations of topical pain relief drugs to product pipeline

Biovitrum extends ReFacto supply agreement with Wyeth

Helion receives funding to continue development of MASP-2

Recent Bayer Schering patent reports novel antiviral agents

Novel NNRTIs reported by Roche

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...